Abstract: A system and method for traversing a firewall for a voice-over-IP session or other communication session uses four main components: a relay agent, and NAT 30Agent, a SIP proxy and a application server. The SIP proxy is located in the public network and SIP signaling messages are routed through the SIP proxy. The sever opens ports in the firewall for signaling between the SIP proxy and the relay agent behind the firewall. The application server also opens ports in the firewall for media traffic. The NAT 30Agent disposed in the path from the firewall to the Internet filters media packets and changes the public source address of the media packets to a predetermined address associated with the open media port.

Abstract: A system and method for traversing a firewall for a voice-over-IP session or other communication session uses four main components: a relay agent, and NAT 30Agent, a SIP proxy and a application server. The SIP proxy is located in the public network and SIP signaling messages are routed through the SIP proxy. The sever opens ports in the firewall for signaling between the SIP proxy and the relay agent behind the firewall. The application server also opens ports in the firewall for media traffic. The NAT 30Agent disposed in the path from the firewall to the Internet filters media packets and changes the public source address of the media packets to a predetermined address associated with the open media port.

Abstract: A system and method for traversing a firewall for a voice-over-IP session or other communication session uses four main components: a relay agent, and NAT 30Agent, a SIP proxy and a application server. The SIP proxy is located in the public network and SIP signaling messages are routed through the SIP proxy. The sever opens ports in the firewall for signaling between the SIP proxy and the relay agent behind the firewall. The application server also opens ports in the firewall for media traffic. The NAT 30Agent disposed in the path from the firewall to the Internet filters media packets and changes the public source address of the media packets to a predetermined address associated with the open media port.

Abstract: Compounds of formula (I): wherein R1, R2, A1, A2, A3, A4, X and Y are as defined herein, are useful as inhibitors of HIV replication.

Abstract: A system and method for traversing a firewall for a voice-over-IP session or other communication session uses four main components: a relay agent, and NAT 30A gent, a SIP proxy and a application server. The SIP proxy is located in the public network and SIP signaling messages are routed through the SIP proxy. The sever opens ports in the firewall for signaling between the SIP proxy and the relay agent behind the firewall. The application server also opens ports in the firewall for media traffic. The NAT 30A gent disposed in the path from the firewall to the Internet filters media packets and changes the public source address of the media packets to a predetermined address associated with the open media port.

Abstract: Compounds of formula I: wherein a, b, c, X, R2, R3, R4, R6 and R7 are defined herein, are useful as inhibitors of HIV replication.

Abstract: Compounds of formula (I): wherein R1, R2, A1, A2, A3, A4, X and Y are as defined herein, are useful as inhibitors of HIV replication.

Abstract: A system and method for traversing a firewall for a voice-over-IP session or other communication session uses four main components: a relay agent, and NAT 30Agent, a SIP proxy and a application server. The SIP proxy is located in the public network and SIP signaling messages are routed through the SIP proxy. The sever opens ports in the firewall for signaling between the SIP proxy and the relay agent behind the firewall. The application server also opens ports in the firewall for media traffic. The NAT 30Agent disposed in the path from the firewall to the Internet filters media packets and changes the public source address of the media packets to a predetermined address associated with the open media port.

Abstract: Compounds of formula I: wherein a, b, c, X, R2, R3, R4, R6 and R7 are defined herein, are useful as inhibitors of HIV replication.

Abstract: A dispenser for depositing at least one of lines and stripes of at least one material, comprising a trolley having front and back wheels and securing at least one container on a platform thereof, the trolley being movable between an in-use position, wherein the trolley is straighten up on the front wheels thereof allowing a content of the at least one container to be out from at least one aperture on a bottom part of the at least one container, and an out-of use position, wherein the trolley rests on rear wheels thereof and the content of the at least one container is stopped from flowing out from the at least one aperture.

Abstract: Compounds represented by formula I: wherein R1 is H, halogen, (C1-4)alkyl, O(C1-4)alkyl, and haloalkyl; R2 is H or (C1-4)alkyl; R3 is H or (C1-4)alkyl; R4 is (C1-4)alkyl, (C1-4)alkyl(C3-7)cycloalkyl, or (C3-7)cycloalkyl; and Q is a fused phenyl-5 or 6-membered saturated heterocycle having one to two heteroatoms selected from O and N, said Q being optionally substituted with hydroxy, or (C1-4)alkyl which in turn maybe optionally substituted with pyridinyl-N-oxide or C(O)OR wherein R is H or (C1-4)alkyl; or a salt thereof. The compounds have inhibitory activity against Wild Type, and single and double mutants strains, of HIV.

Abstract: A parapet wall comprising posts, each post being fastened to a siding of a building by a post fastening means, and heddles connected between the posts, the post fastening means being fastened to the siding of the building on the one hand and to an edge of a roof of the building on the other hand, along a direction generally perpendicular to the siding of the building, by a mounting plate including a first part fastened to the edge of the roof and a second part accommodating a foot of the post.

Abstract: Compounds represented by formula I: wherein R2 is selected from the group consisting of H, (C1-4)alkyl, halo, haloalkyl, OH, (C1-6)alkoxy, NH(C1-4alkyl) or N(C1-4alkyl)2; R4 is H or Me; R5 is H or Me; R11 is H, (C1-4)alkyl, (C3-4)cycloalkyl and (C1-4)alkyl-(C3-4)cycloalkyl; A is a connecting chain of (C1-3)alkyl; B is O or S; n is 0 or 1; wherein when n is 0: Ring C is 6- or 10-membered aryl or 5- or 6-membered heterocycle having from 1 to 4 heteroatoms selected from the group consisting of O, N, and S, said aryl and said heterocycle being optionally substituted; and E is CONR12R13; CONHNR14R15; NR16COR17; NR18SO2(C1-6)alkyl; SO2NR19R20; or SO2R21; or when n is 1: Ring C is as defined above and E is a single bond or a connecting group; and Ring D is 6- or 10-membered aryl or 5- or 6-membered heterocycle having from 1 to 4 heteroatoms selected from the group consisting of O, N, and S, said aryl and said heterocycle being optionally substituted with from 1 to 5 substituents; or a salt or

Abstract: Compounds represented by formula I: 1

Abstract: Compounds represented by formula I: 1

Abstract: A compound of formula 1: wherein Y is S or O; R1 is C1-6 alkyl; (C0-6 alkyl)aryl; (C0-6 alkyl)Het; or R1 is an amino acid analog or dipeptide analog of the formula: wherein R2 is H, C1-10 alkyl; or an amide or ester group; A is C6-10 aryl, Het or CH—R3 wherein R3 is C1-6 alkyl or (C0-4 alkyl)aryl; and Z is H, C1-6 alkyl, or an acyl; R4 is hydrogen, lower alkyl, methoxy, ethoxy, or benzyloxy; and R5 is alkyl, cycloalkyl, carboxyl group; an aryl; Het or Het(lower alkyl); or R4 and R5 together with the nitrogen atom to which they are attached form a nitrogen containing ring optionally substituted with phenyl or C(O)OCH2-phenyl, said phenyl ring optionally mono- or di-substituted with among others C(O)OR7 wherein R7 is lower alkyl or phenyl(lower alkyl); or a therapeutically acceptable acid addition salt thereof which compounds are useful in the treatment of HCMV infections.

Abstract: Disclosed herein is a process for preparing (S)-.alpha.-amino-1-carboxycyclopentaneacetic acid which is a useful intermediate for preparing peptidomimetic inhibitors of herpes viral ribonucleotide reductase. The process comprises the preparation of the key intermediate ##STR1## and its subsequent conversion to the desired product.